Personalized neck radiation for nasopharyngeal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 trial evaluates the effectiveness of individualized elective neck irradiation for patients with nasopharyngeal carcinoma (NPC) based on the vertebral level of metastatic lymph nodes. The study aims to determine if this tailored approach can reduce radiation-related side effects and enhance patients' quality of life while maintaining survival rates. By utilizing advanced imaging techniques like MRI and PET-CT, the trial seeks to accurately assess lymph node involvement and optimize treatment. The hypothesis is that targeted irradiation will lead to fewer adverse effects compared to standard whole-neck irradiation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The eligibility criteria are: newly diagnosed, untreated, non-distant metastatic, and non-keratinizing NPC; nodes are diagnosed with PET/CT and MRI; staged as T1-4N0-2 or N3 category of non-bilateral lower-neck node metastasis; aged between 18 and 70 years; Karnofsky performance-status score \> 70; adequate haematological function, with a leucocyte count \> 4 × 109/L, haemoglobin \> 90 g/L, and a thrombocyte count \> 100×109/L

Exclusion Criteria:

* The exclusion criteria include: previous chemotherapy treatment, surgery (except diagnostic) or radiotherapy to the neck or nasopharyngeal regions; previous malignancy; lactation or pregnancy; or severe coexisting illness.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Ling-Long Tang, Prof
• Email: tangll@sysucc.org.cn
• Phone: 02087343840

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Induction and maintenance with MRG003, Tislelizumab, and Capecitabine for locally recurrent nasopharyngeal cancer

  This study tests a treatment combo of MRG003 and a PD-1 blocker first, then continues with Capecitabine plus the PD-1 blocker to see if it helps patients with locally recurrent NPC.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07331428

• Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer

  This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.

  Recruiting at 15 sites Phase 3 Sun Yat-sen University · Hefei, Anhui and 14 other locations · NCT07328854

• Screening for early nasopharyngeal (nose) cancer

  This project tests whether blood and saliva markers can find nasopharyngeal cancer early in adults aged 35 to 60 who are at higher risk because of ethnicity or family history.

  Recruiting at 2 sites National University Hospital, Singapore · Singapore and 1 other locations · NCT07019870

• Proton versus photon radiation for nasopharyngeal cancer

  This trial will test whether proton radiation works at least as well as standard photon radiation for adults newly diagnosed with nasopharyngeal cancer that has not spread.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan · NCT07000643

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.